Bridger Aerospace's Record 2025 Masks Persistent Covenant and Contract Risks

What happened

Bridger Aerospace executives reported record operational and financial performance for 2025 during their Q4 earnings call, highlighting increased utilization despite a below-average fire year. They updated fleet expansion and contracting plans for 2026, alongside initial guidance, portraying confidence in scaling capabilities. However, DeepValue analysis reveals underlying high leverage of $173.2M net debt and tight covenants requiring minimum operating cash flow of $30M, which gate growth. The company's strategy depends on converting new aircraft capacity into named exclusive-use contracts for 2026, a critical step not yet confirmed in the earnings update. Without these contracts, covenant breaches could force dilution via a fully available $100M ATM facility, keeping investment risk elevated despite positive headlines.

Implication

The record performance in 2025 demonstrates operational efficiency but does not mitigate the high leverage and covenant constraints detailed in filings, which could trigger dilution if unmet. Bridger's ability to grow hinges on securing named exclusive-use contracts for its expanded fleet in 2026, a key uncertainty highlighted in the DeepValue report as a thesis breaker. Absent these contracts, the company risks covenant non-compliance, potentially forcing equity issuance through the $100M ATM facility and eroding shareholder value. The updated plans and guidance lack specific contract awards, leaving the thesis unproven and maintaining binary outcomes around contract conversion. Therefore, investors should await clear evidence of contract awards in the next 3-6 months before making decisions, aligning with the WAIT rating and avoiding premature entry.

Thesis delta

The earnings call reinforces Bridger's operational strength but does not shift the investment thesis, as key risks around 2026 contract awards and covenant durability remain unresolved. No new information was provided on named contracts or covenant headroom, keeping the core thesis dependent on near-term catalyst monitoring. Thus, the WAIT rating and focus on contract conversion over the next 3-6 months remain appropriate.